United States
After the US presidential election and looking ahead to a new year, most companies are still wondering when the world will return to normal.
Life sciences companies must address the growing trove of data as they seek to bring personalized therapies, drugs and devices to market.
How can middle market pharmaceutical companies meet pricing reform demands while remaining competitive in the marketplace?